首页> 外文期刊>Xenobiotica: the fate of foreign compounds in biological systems >The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: From obscure liver transporters to key determinants of hepatobiliary clearance
【24h】

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: From obscure liver transporters to key determinants of hepatobiliary clearance

机译:DMPK科学中OATP肝脏摄取转运蛋白家族的演变:从晦涩的肝脏转运蛋白到肝胆清除率的关键决定因素

获取原文
获取原文并翻译 | 示例
           

摘要

Over the last two decades the impact on drug pharmacokinetics of the organic anion transporting polypeptides (OATPs: OATP-1B1, 1B3 and 2B1), expressed on the sinusoidal membrane of the hepatocyte, has been increasingly recognized. OATP-mediated uptake into the hepatocyte coupled with subsequent excretion into bile via efflux proteins, such as MRP2, is often referred to as hepatobiliary excretion. OATP transporter proteins can impact some drugs in several ways including pharmacokinetic variability, pharmacodynamic response and drug-drug interactions (DDIs). The impact of transporter mediated hepatic clearance is illustrated with case examples, from the literature and also from the Pfizer portfolio. The currently available in vitro techniques to study the hepatic transporter proteins involved in the hepatobiliary clearance of drugs are reviewed herein along with recent advances in using these in vitro data to predict the human clearance of compounds recognized by hepatic uptake transporters.
机译:在过去的二十年中,越来越多地认识到在肝细胞的正弦膜上表达的有机阴离子转运多肽(OATP:OATP-1B1、1B3和2B1)对药物药代动力学的影响。 OATP介导的肝细胞摄取以及随后通过外排蛋白(例如MRP2)排入胆汁通常被称为肝胆排泄。 OATP转运蛋白可以几种方式影响某些药物,包括药代动力学变异性,药效学反应和药物-药物相互作用(DDI)。案例说明了转运蛋白介导的肝清除的影响,这些案例来自文献以及辉瑞公司的产品组合。本文回顾了目前可用于研究涉及药物肝胆清除的肝转运蛋白的体外技术,以及使用这些体外数据预测人类被肝摄取转运蛋白识别的化合物的清除方面的最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号